Ensign Peak Advisors’s Milestone Pharmaceuticals MIST Stock Holding History

Ensign Peak Advisors’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-69,422	Closed	-$638K	–	2049
2022 Q3	$638K	Buy	+69,422	New	+$527K	﹤0.01%	1334

Other funds holding MIST

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ensign Peak Advisors's MIST Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Milestone Pharmaceuticals (MIST) in Q4 2022, closing a stake of 69,422 shares — an estimated $638K sold.

Ensign Peak Advisors first reported a position in MIST in Q3 2022 and held it in 1 quarter. The position peaked at $638K in Q3 2022. 56 funds tracked by Wall St. Rank hold MIST as of Q4 2022.

Ensign Peak Advisors reported no remaining Milestone Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Ensign Peak Advisors sold 69,422 Milestone Pharmaceuticals shares in Q4 2022, an estimated $638K.
Ensign Peak Advisors first reported a position in Milestone Pharmaceuticals in Q3 2022 and held it in 1 quarter.
Ensign Peak Advisors's Milestone Pharmaceuticals position peaked at $638K in Q3 2022.
56 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.